» Articles » PMID: 2078310

Brain Iron and Ferritin in Parkinson's and Alzheimer's Diseases

Overview
Date 1990 Jan 1
PMID 2078310
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

Semiquantitative histological evaluation of brain iron and ferritin in Parkinson's (PD) and Alzheimer's disease (DAT) have been performed in paraffin sections of brain regions which included frontal cortex, hippocampus, basal ganglia and brain stem. The results indicate a significant selective increase of Fe3+ and ferritin in substantia nigra zona compacta but not in zona reticulata of Parkinsonian brains, confirming the biochemical estimation of iron. No such changes were observed in the same regions of DAT brains. The increase of iron is evident in astrocytes, macrophages, reactive microglia and non-pigmented neurons, and in damaged areas devoid of pigmented neurons. In substantia nigra of PD and PD/DAT, strong ferritin reactivity was also associated with proliferated microglia. A faint iron staining was seen occasionally in peripheral halo of Lewy bodies. By contrast, in DAT and PD/DAT, strong ferritin immunoreactivity was observed in and around senile plaques and neurofibrillary tangles. The interrelationship between selective increase of iron and ferritin in PD requires further investigation, because both changes could participate in the induction of oxidative stress and neuronal death, due to their ability to promote formation of oxygen radicals.

Citing Articles

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

Jozwiak M, Bauer M, Kamysz W, Kleczkowska P Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005999 PMC: 11859134. DOI: 10.3390/ph18020185.


Perturbations in levels of essential metals less severe in Parkinson's disease without dementia than in Parkinson's disease dementia.

Scholefield M, Church S, Cooper G Metallomics. 2025; 17(3).

PMID: 39933566 PMC: 11895508. DOI: 10.1093/mtomcs/mfaf006.


Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson's Disease Mice.

Huang Y, Wang X, Li W, Yue F, Wang M, Zhou F Int J Nanomedicine. 2024; 19:10401-10414.

PMID: 39430307 PMC: 11490209. DOI: 10.2147/IJN.S479670.


Microglial senescence in neurodegeneration: Insights, implications, and therapeutic opportunities.

Samuel Olajide T, Oyerinde T, Omotosho O, Okeowo O, Olajide O, Ijomone O Neuroprotection. 2024; 2(3):182-195.

PMID: 39364217 PMC: 11449118. DOI: 10.1002/nep3.56.


Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis.

Negida A, Hassan N, Aboeldahab H, Zain Y, Negida Y, Cadri S CNS Neurosci Ther. 2024; 30(2):e14607.

PMID: 38334258 PMC: 10853946. DOI: 10.1111/cns.14607.